Indeed, Roemer et al. also reported that β2-microglobulin (β2M) and MHC-I were not expressed on tumor cells in more than 60% of HL patients and that the expression level of MHC-II and PD-L1 predicts therapeutic response to nivolumab in HL patients [72]. This evidence concerns the gene B2M and Hodgkins lymphoma.